Citations

Clear

590 citation(s) found for "Ho, Ben".

Prevalence of Hidradenitis Suppurativa
Hagan, Paa Gyasi, Botvid, Sofia , Hove, Lone Storgaard, Christensen, Robin , Group, GHiSA, Knecht-Gurwin, Klaudia , Zobiri, S., Serradj, A. , Noor, Towhida , Guillem, Philippe , Parvizi, Mohammad Mahdi , Vardar, Caner, Maharbi, Waleed H. A. Al, Huijstee, Johanna C. van , Aarts, Pim , Dewi, Shinta Trilaksmi , Indrastuti, Niken , Suryawati, Nyoman , Adji, Aryani , Akhyar, Gardenia , Nopriyati, Nopriyati, Reyes‐Baraona, Francisco, Matas, Carlos, Saeed, Haroon , Moodley, Ameshin , Binamer, Yousef , Kamil, Moonyza Akmal Ahmad , Jocic, Ivana , Mijušković, Željko, Mallawaarachchi, Kanchana , Gangani, Chathurika, Tusheva, Ivana , Boshkovski, Vesna Brishkoska , Hu, Danchen , Medianfar, Cecilia E. , Benhadou, Farida , Naik, Haley B. , Boer, Jurr , Bouazzi, Dorra , Nielsen, Sabrina Mai , Prens, Errol P. , Jemec, Gregor B. E. , Group, GHiSA, Szepietowski, Jacek C. , Anaba, Ehiaghe L. , Chehad, Ahmed Samaouel , Bhuiyan, Mohammed Saiful Islam , Saki, Nasrin , Alpsoy, Erkan , Kanni, Theodora , Giamarellos‐Bourboulis, Evangelos J. , Frew, John W. , Maharbi, Waleed AL, Febriana, Sri Awalia , Pangastuti, Miranti , Nopriyati, Nopriyati , Hazlianda, Cut Putri , Matas, Carlos, Saeed, Haroon, Geng, Songmei , Saunte, Ditte Marie Lindhardt , Chandran, Nisha Suyien , Zee, Hessel H. van der , Zouboulis, Christos C. , Villumsen, Bente , Alavi, Afsáneh , Ibekwe, Perpetua U. , Hamzavi, Iltefat H. , Ingram, John R , Garg, Amit

Mayo Clinic

JAMA Dermatology | August 27, 2025 | Volume: 161 | Issue: 10 | Pages: 1022

10.1001/jamadermatol.2025.2373 | PMID 40864454 Get It

Importance Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a substantial burden. Standardized global prevalence estimates and data on associated sociodemographic and risk factors are lacking. Objective To estimate the global prevalence of HS and study differences in prevalence by age, sex, geographical location, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), smoking status, gross domestic product (GDP), and Human Development Index (HDI). Data Sources and Study Selection Included studies were conducted using the standardized Global Hidradenitis Suppurativa Atlas methodology with finalized data collection before May 19, 2023. Studies were required to use a population-based sampling method and conduct clinical confirmation of HS diagnosis following a screening questionnaire. Data Extraction and Synthesis Data were independently extracted from relevant studies by 2 reviewers (D.B. and C.E.M.) using a standardized form. Extracted variables included geographic location, age, sex, BMI (median and BMI >30), smoking status, HS prevalence estimates (with 95% CIs), GDP, and HDI. A proportional meta-analysis using a random-effects model was conducted on the included studies. Main Outcomes and Measures The primary outcome was the point prevalence of HS, confirmed by clinical examination. Secondary outcomes included differences in HS prevalence by sex, age, BMI category, smoking status, and country-level socioeconomic indicators (GDP and HDI). All outcomes were prespecified before data analysis. Results The sample included 22 743 participants, identifying 247 patients with HS, across 25 studies in 23 countries spanning 6 continents. The median proportion of female patients with HS was 55.6%, and the median age was 34.5 years. While the prevalence estimates showed considerable inconsistency ( I 2 > 75%; τ 2 = 0.747), the overall random-effects global prevalence of HS was 0.99% (95% CI, 0.67%-1.46%). Female sex was the only factor observed to be associated with the prevalence estimates (β = 1.02; 95% CI, 1.01-1.03). Conclusions and Relevance In this meta-analysis, an estimated global prevalence of HS between 0.67% and 1.46% surpassed previous global estimates. Substantial global variations in HS prevalence were also observed. Female sex was the only factor associated with prevalence in this sample. Future studies assessing genetic, environmental, and etiological factors are warranted to explain the heterogeneity in prevalence.
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma
Greenbaum, Uri , Hashmi, Hamza , Elsawy, Mahmoud , Kim, Soyoung , Moskop, Amy , Oloyede, Temitope, Awan, Farrukh T. , Bachanová, Veronika , Badar, Talha , Bar, Merav , Barba, Pere , Cashen, Amanda F. , Ganguly, Siddhartha , Kittai, Adam S. , Lulla, Premal , Mead, Elena, Geethakumari, Praveen Ramakrishnan , Saber, Wael , Strouse, Christopher , Valluripalli, Anusha, Wudhikarn, Kitsada , Pasquini, Marcelo C. , Dholaria, Bhagirathbhai R , Farooq, Umar , Hematti, Peiman , Hill, LaQuisa C , Jain, Michael D , Jain, Tania , Lulla, Premal D , McGuirk, Joseph , Mussetti, Alberto , Nishihori, Taiga , Olson, Amanda L , Perales, Miguel-Angel , Riedell, Peter A , Shouval, Roni , Magalhaes-Silverman, Margarida , Pasquini, Marcelo , Ahmed, Sairah , Sorror, Mohamed , Bachanova, Veronika , Badar, Talha , Strouse, Christopher S , Awan, Farrukh T , Kim, Soyoung , Moskop, Amy , Beitinjaneh, Amer , Dholaria, Bhagirathbhai , Foglesong, Jessica , Hematti, Peiman , Hill, LaQuisa C. , Jain, Michael D. , Jain, Tania , Kebriaei, Partow , Locke, Frederick L. , McGuirk, Joseph P. , Mussetti, Alberto , Nishihori, Taiga , Pennisi, Martina , Perales, Miguel‐Angel , Riedell, Peter A. , Shpall, Elizabeth J. , Magalhaes‐Silverman, Margarida , Turtle, Cameron J. , Vallurupalli, Anusha , Ahmed, Sairah , Sorror, Mohamed L.

Mayo Clinic

Blood Advances | August 14, 2025 | Volume: 10 | Issue: 1 | Pages: 217-227

10.1182/bloodadvances.2024015599 | PMID 40811818 Get It

Abstract The cumulative impact of baseline comorbidities on outcomes of chimeric antigen receptor T-cell (CAR-T) therapy is not well established. Therefore, we developed and validated a Cellular Therapy Comorbidity Index (CT-CI) to predict outcomes following CD19-directed CAR-T therapy for large B-cell lymphoma (LBCL). Patients aged 18 or older receiving commercial CAR-T therapy for LBCL during 2017 to 2020 were selected from the Center for International Blood and Marrow Transplant Research registry. Patients were randomly assigned to training or validation cohorts. Comorbidities given weighted scores comprised the CT-CI, which was then validated for overall survival (OS) prognostication. A total of 1916 patients from 97 medical centers were included, with a median age of 64 years (19-91 years). About 70% of patients had comorbidities, such as cardiac disease (12%); diabetes (14%); hepatic dysfunction (mild, 8%; moderate to severe, 2%); psychiatric disturbance (18%); and pulmonary dysfunction (moderate, 15%; severe, 12%). The CT-CI was calculated, stratified patients in 3 categories, and was associated with increased mortality. Patients with higher CT-CI scores had worse OS (CT-CI 1: hazard ratio [HR], 1.37 [95% confidence interval [CI], 1.16-1.62; P< .001]; CT-CI 2: HR, 1.49 [95% CI, 1.17-1.89; P = .001]; CT-CI ≥ 3: HR, 2.55 [95% CI, 1.90-3.42; P< .001]). Higher CT-CI scores predicted treatment-related mortality and relapse. There was no correlation between the CT-CI score and CAR-T–related toxicities. The novel CT-CI score stratifies the effect of patient comorbidities on survival after CAR-T therapy and can be used for clinical decision-making and treatment selection in high-risk populations. However, comorbidities and fear of increased toxicity should not preclude patients from this effective therapy.
Brain signatures of nociplastic pain: Fibromyalgia Index and descending modulation at population level
Kelleher, Eoin , Wanigasekera, Vishvarani , Seymour, Ben , Segerdahl, Andrew R. , Irani, Anushka , Kelleher, Eoin M , Seymour, Ben , Segerdahl, Andrew Reilly , Irani, Anushka , Lange, Frederik , Rathod‐Mistry, Trishna , Nichols, Thomas E. , Tracey, Irene

Mayo Clinic

Brain | August 14, 2025 | Volume: 149 | Issue: 4 | Pages: 1365-1380

10.1093/brain/awaf307 | PMID 40819274 Get It

Abstract Nociplastic pain is defined by altered nociceptive processing in the absence of clear peripheral damage or somatosensory lesions. The Fibromyalgia Index (FMI), derived from the 2016 diagnostic criteria, is increasingly used as a marker of nociplastic pain severity in clinical studies, yet its neurobiological validity remains untested at scale. Using multimodal neuroimaging data from over 40 000 participants in UK Biobank, we examined whether FMI scores were associated with altered functional and structural connectivity within the descending pain modulatory system (DPMS), a brain network involved in endogenous pain control and implicated in nociplastic pain conditions. Functional connectivity was assessed using resting-state functional MRI (rfMRI), and structural connectivity using diffusion-weighted MRI (dMRI) tractography. Connectivity was quantified between seven DPMS regions: periaqueductal grey (PAG), rostral ventromedial medulla (RVM), hypothalamus, amygdala, rostral and subgenual anterior cingulate cortex (rACC, sgACC), and dorsolateral prefrontal cortex (dlPFC). Multi-group structural equation models tested associations between FMI scores and connectivity, stratified by chronic pain status. Mediation models evaluated which aspects of nociplastic pain accounted for the observed associations: widespread pain and SPACE symptoms (sleep disturbance, pain, affect, cognitive problems, and low energy). To assess specificity, we repeated analyses using the Douleur Neuropathique 4 (DN4), a measure of neuropathic pain, and average pain intensity as comparison outcomes. In 22 139 individuals with chronic pain (58% female; mean age 64.8, standard deviation 7.59), FMI scores were associated with altered structural connectivity between the PAG and amygdala [β = 0.023, 95% confidence interval (CI): 0.0087 to 0.039; Pcorr = 0.0125] and between the PAG and hypothalamus (β = −0.029, 95% CI: −0.043 to −0.015; Pcorr = 0.0013). Functional connectivity in the same circuits showed smaller effects. These associations were not observed in individuals without chronic pain. Mediation analyses revealed that PAG-amygdala and PAG-hypothalamus connectivity were partially explained by fatigue, sleep duration, and widespread pain. DPMS connectivity was not significantly associated with neuropathic pain or average pain intensity. These findings suggest that FMI scores reflect biologically meaningful changes in brain connectivity, particularly in subcortical DPMS circuits implicated in affective and homeostatic dimensions of pain. Structural connectivity was more strongly associated with FMI than functional measures, possibly reflecting cumulative effects of chronic pain on white matter architecture. The absence of similar associations for other pain outcomes supports the specificity of FMI as a marker of nociplastic pain severity. These results provide a neurobiological basis for the FMI and support its use in population research and biomarker development for nociplastic pain.
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Epstein‐Peterson, Zachary D. , Lionel, Anath C. , Joseph, Ashlee , Drill, Esther , Atallah‐Yunes, Suheil Albert , Brooks, Taylor , Chong, Elise A. , Chong, Emeline R. , Cruz, Jamie Dela , Frank, Matthew J. , Jacobson, Caron A. , Beyar‐Katz, Ofrat , Maddocks, Kami J. , McLoughlin, Daniel E. , Navalekar, Rohin, Ryan, Christine E. , Sauter, Craig S. , Sharma, Samanvaya , Shukla, Navika , Therwhanger, Dylan , Besien, Herman J. van, Varon, Ben , Yamshon, Samuel , Palomba, M. Lia , Kumar, Anita , Brooks, Taylor R , Kamdar, Manali , Karmali, Reem , Matasar, Matthew , McLoughlin, Daniel , Rhodes, Joanna , Riedell, Peter A , Ryan, Christine E , Salles, Gilles A , Sawalha, Yazeed , Sharma, Samanvaya , Shouval, Roni , Therwhanger, Dylan , van Besien, Herman , Varon, Ben , Wang, Yucai , Yamshon, Samuel , Zelenetz, Andrew D , Jain, Preetesh , Kumar, Anita , Chong, Elise A , Joseph, Ashlee , Atallah-Yunes, Albert , Ip, Andrew , Iqbal, Madiha , Kamdar, Manali , Karmali, Reem , Matasar, Matthew J. , Merryman, Reid W. , Muñoz, Javier , Navalekar, Rohini, Rhodes, Joanna , Riedell, Peter A. , Salles, Gilles , Sawalha, Yazeed , Wang, Yucai , Zelenetz, Andrew D. , Jain, Preetesh

Mayo Clinic

Blood Advances | August 5, 2025 | Volume: 9 | Issue: 21 | Pages: 5654-5662

10.1182/bloodadvances.2025016315 | PMID 40763269 Get It

Abstract The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post–CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to CAR T-cell therapy. Tumor features at POD included blastoid/pleomorphic morphology in 29 of 78 (37%) patients, and TP53 mutation in 21 of 41 (51%) patients. Following POD, 17 patients received no further therapy, 13 underwent local therapy, and 105 received systemic therapy. The most common first-line systemic therapies were chemo(immuno)therapy (22 patients; overall response rate [ORR], 40%), pirtobrutinib (17 patients; ORR, 36%), and bispecific antibodies (13 patients; ORR, 67%). Among patients experiencing POD, the median progression-free survival and overall survival (OS) were 2.5 months and 5.4 months, respectively, from POD. Lack of response to CAR T-cell therapy and short time from CAR T-cell therapy infusion to POD (<3 vs 3-6 vs >6 months), among other factors, were associated with inferior OS after POD. In conclusion, we confirm the challenging prognosis for patients experiencing POD following CD19 CAR T-cell therapy for R/R MCL, and establish a benchmark for future investigations in this patient population.
Sensitivity of Diffusion Tensor Imaging for Assessing Injury Severity in a Rat Model of Isolated Diffuse Axonal Injury: Comparison with Histology and Neurological Assessment
Zvenigorodsky, Vladislav , Gruenbaum, Benjamin F. , Shelef, Ilan , Frank, Dmitry , Tsafarov, Beatris, Negev, Shahar, Zeldetz, Vladimir, Azab, Abed N., Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Boyko, Matthew , Shelef, Ilan , Zlotnik, Alexander Anatolievich

Mayo Clinic

International Journal of Molecular Sciences | July 29, 2025 | Volume: 26 | Issue: 15 | Pages: 7333

10.3390/ijms26157333 | PMID 40806467 Get It

Diffuse axonal brain injury (DAI) is a common, debilitating consequence of traumatic brain injury, yet its detection and severity grading remain challenging in clinical and experimental settings. This study evaluated the sensitivity of diffusion tensor imaging (DTI), histology, and neurological severity scoring (NSS) in assessing injury severity in a rat model of isolated DAI. A rotational injury model induced mild, moderate, or severe DAI in male and female rats. Neurological deficits were assessed 48 h after injury via NSS. Magnetic resonance imaging, including DTI metrics, such as fractional anisotropy (FA), relative anisotropy (RA), axial diffusivity (AD), mean diffusivity (MD), and radial diffusivity (RD), was performed prior to tissue collection. Histological analysis used beta amyloid precursor protein immunohistochemistry. Sensitivity and variability of each method were compared across brain regions and the whole brain. Histology was the most sensitive method, requiring very small groups to detect differences. Anisotropy-based MRI metrics, especially whole-brain FA and RA, showed strong correlations with histology and NSS and demonstrated high sensitivity with low variability. NSS identified injury but required larger group sizes. Diffusivity-based MRI metrics, particularly RD, were less sensitive and more variable. Whole-brain FA and RA were the most sensitive MRI measures of DAI severity and were comparable to histology in moderate and severe groups. These findings support combining NSS and anisotropy-based DTI for non-terminal DAI assessment in preclinical studies.
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study
Collinge, Brett , Hilton, Laura K. , Wong, Jasper , Alduaij, Waleed , Ben‐Neriah, Susana , Slack, Graham W. , Farinha, Pedro , Boyle, Merrill, Meissner, Barbara , Cook, James R. , Ott, G., Rosenwald, Andreas , Amador, Catalina , Greiner, Timothy C. , Ondrejka, Sarah L. , Weisenburger, Dennis D. , Beiske, Klaus , Fu, Kai , Iqbal, Javeed , Wright, George, Staudt, Louis M. , Boyle, Merrill , Campo, Elías , Amador, Catalina , Greiner, Timothy C , Inghirami, Giorgio , Ondrejka, Sarah , Jaffe, Elaine S , Holte, Harald , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J , Mungall, Andrew J , Steidl, Christian , Feldman, Andrew L , Morin, Ryan D , Scott, David W , Iqbal, Javeed , Alduaij, Waleed , Farinha, Pedro , Hilton, Laura K , Campo, Elı́as , Raess, Philipp W. , Song, Joo Y. , Inghirami, Giorgio , Jaffe, Elaine S. , Chan, Wing C., Holte, Harald , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J. , Mungall, Andrew J. , Steidl, Christian , Feldman, Andrew L. , Rimsza, Lisa M. , Scott, David W.

Mayo Clinic

Blood Advances | July 17, 2025 | Volume: 9 | Issue: 21 | Pages: 5409-5422

10.1182/bloodadvances.2025016651 | PMID 40674706 Get It

Abstract Molecular characterization of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS), is hindered by its rarity, evolving definition, and poor diagnostic reproducibility. To address this challenge, we analyzed 92 HGBCL-NOS tumors collected across Lymphoma/Leukemia Molecular Profiling Project sites. Leveraging comparison cohorts of diffuse large B-cell lymphoma, NOS (DLBCL-NOS) and Burkitt lymphoma (BL), and molecular frameworks described in these entities, our analysis revealed a heterogenous molecular landscape, reminiscent of DLBCL-NOS but with an enrichment of BL features. By cell-of-origin classification, 59% were germinal center B-cell–like (GCB), and 25% were activated B-cell–like (ABC). LymphGen, a genetic classifier for DLBCL-NOS, assigned a genetic subtype to 34% of HGBCL-NOS. Although classification rate was lower than in DLBCL-NOS (66%), assigned subtypes spanned the spectrum of LymphGen classes, including 31% of ABCs classified as MCD. Features differentiating HGBCL-NOS from DLBCL-NOS included MYC rearrangement (47% vs 6%); dark zone signature (DZsig) expression (45% vs 7%); and more frequent mutation of ID3, MYC, CCND3, and TP53, all common to BL. A genetic classifier that differentiates DLBCL-NOS from BL classified 53% of DZsig+ tumors as BL-like, and those classified as DLBCL-like were frequently BCL2-rearranged. Among DZsig− GCB tumors, 95% were DLBCL-like. Centralized pathology review reclassified almost half of tumors as DLBCL-NOS but did not identify a more homogenous HGBCL-NOS population, with no difference in features between confirmed and reclassified tumors. In conclusion, molecular testing enables a subset of HGBCL-NOS to be assigned to established categories. Based on rarity and diagnostic challenges, broader inclusion of HGBCL-NOS should be considered in biomarker-driven DLBCL trials.
E-194 Microstructural brain changes assessment using neurite orientation dispersion and density imaging (NODDI) in a rodent stroke model of thrombectomy on a clinical 3T MR-scanner
Moëlo, Cloé , Caron, Margot , Chéchin, D., Kadirvel, Ramanathan , Ognard, Julien , Caron, M, Hajj, G El , Salem, D. Ben , Timsit, Serge

Mayo Clinic

SNIS 22nd annual meeting electronic poster abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A224.1-A224

10.1136/jnis-2025-snis.309 Get It

Phase 2a Study of Baxdrostat in Primary Aldosteronism
Freeman, Mason W. , Ben-Shlomo, Anat , Huang, Wenyu , Kirschner, Lawrence S. , Sam, Ramin , Tuyishimire, Bonifride, Lihn, Aina Sætre, Perl, Shira, Brown, Morris Jonathan , Turcu, Adina F. , Bancos, Irina , Hamidi, Oksana , Hamrahian, Amir Hekmat , Mallappa, Ashwini

Mayo Clinic

New England Journal of Medicine | July 13, 2025 | Volume: 393 | Issue: 5 | Pages: 515-518

10.1056/nejmc2508629 | PMID 40658651 Get It

Supporting the Deceased, Their Families, and Their Communities – Part 2: Practical Guidance for Building an Office of Decedent Affairs
Chambers, Meagan , Bartholow, Tanner, Parker, Zachary T., Peters, Kristina, Reichard, R. Ross , Tigard, Charles, Hooper, Jody E. , Benson, Paul , Davis, Ronnie, Cool, Robert, Beglarian, Ben, Mount, Sharon , Jackson, Nicole R. , Marshall, Desiree A. , Harcourt, Lisbeth, Wiley, LaTresa E., Comstock, Jessica, Hyland, Courtney, Harper, Holly , Priemer, David S. , Rapkiewicz, Amy , Rojiani, Amyn M. , Sanchez, Harold, Parker, Zachary T., Peters, Kristina, Luthringer, Daniel , Davis, Ronnie, Scherpelz, Kathryn P. , Sinard, John H. , Chen, Sonja

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 8, 2025 | Volume: 149 | Issue: 12 | Pages: 1077-1083

10.5858/arpa.2025-0094-oa | PMID 40626859 Get It

Context.— After-death care can be complicated and time-consuming for clinical staff, and frustrating for bereaved families. Delays and errors can have damaging legal and reputational consequences for hospitals. Offices of Decedent Affairs (ODAs) have been proposed as a solution, and their potential benefits have been described in several single institution reports. The literature lacks a contemporary and comprehensive review of existing ODAs and their approaches. Objective.— To describe the process of establishing a new ODA and to provide a snapshot of the spectrum of structure, function, and impact of existing ODAs in the United States. Design.— A survey was administered to 11 established ODAs spread across the continental United States. Programs were identified through the College of American Pathologists Autopsy Committee and a Medical Autopsy Listserv. Results.— Eleven ODAs returned the survey, representing more than 190 cumulative years of experience in decedent care in the hospital setting (median, 10 years). There was a wide range in staffing (both staff size and background) as well as scope of services offered. The median ratio of hospital deaths to full-time equivalent (FTE) staffing was 360 deaths per FTE. Respondents reported that ODAs unburden clinical providers and facilitate decedent management. Some respondents reported a quicker turnover of hospital beds and shorter intervals between pronouncement of death and autopsy. ODAs increased autopsy rates when the autopsy services were part of the ODA. Conclusions.— This survey provides practical information for hospitals considering establishing a new ODA and useful benchmarks for existing ODA programs.
Supporting the Deceased, Their Families, and Their Communities – Part 1: Why Establish an Office of Decedent Affairs
Chambers, Meagan , Bartholow, Tanner, Parker, Zachary T., Peters, Kristina, Reichard, R. Ross , Tigard, Charles, Hooper, Jody E. , Benson, Paul , Davis, Ronnie, Cool, Robert, Beglarian, Ben, Mount, Sharon , Jackson, Nicole R. , Marshall, Desiree A. , Harcourt, Lisbeth, Wiley, LaTresa E., Comstock, Jessica, Hyland, Courtney, Harper, Holly , Priemer, David S. , Rapkiewicz, Amy , Rojiani, Amyn M. , Sanchez, Harold, Parker, Zachary T., Peters, Kristina, Luthringer, Daniel , Davis, Ronnie, Scherpelz, Kathryn P. , Sinard, John H. , Chen, Sonja

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 8, 2025 | Volume: 149 | Issue: 12 | Pages: 1072-1076

10.5858/arpa.2025-0090-oa | PMID 40626861 Get It

Context.— Decedent Affairs Offices and Programs can serve as an avenue to assist medical centers in facilitating efficient and comprehensive decedent management, despite a paucity of literature on their roles, establishment, and efficacy. Objective.— To characterize the motivations and rationales for establishing Decedent Affairs Offices. Design.— A survey was administered to 11 established Decedent Affairs Offices/Programs, identified through the College of American Pathologists Autopsy Committee and a Medical Autopsy Listserv. The questions comprehensively cover establishment, operations, and outcomes data available by institution. Results.— Survey respondents reported the rationale for starting their programs and the benefits such offices can have. Conclusions.— Decedent Affairs Offices and Programs provide a useful option to medical centers to navigate the increasingly complex task of comprehensive decedent management. The present survey helps to delineate the similarities and differences between these programs at 11 institutions, to aid nascent programs in their establishment and growth over time.